Hosted on MSN13h
Chardan Capital Downgrades CervoMed (CRVO)
Fintel reports that on December 11, 2024, Chardan Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...
Hosted on MSN13h
D. Boral Capital Downgrades CervoMed (CRVO)
Fintel reports that on December 10, 2024, D. Boral Capital downgraded their outlook for CervoMed (NasdaqCM:CRVO) from Buy to ...
CervoMed price target lowered to $4 from $45 at Roth MKM
Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company has reported ...
Morgan Stanley downgrades CervoMed (CRVO) to a Sell
CervoMed (CRVO – Research Report) received a Sell rating and price target from Morgan Stanley analyst Jeffrey Hung today. The company’s ...
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint
CervoMed (CRVO) announced topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for the treatment of patients with dementia with Lewy bodies. DLB. The trial did not meet ...
bovnews9h
CervoMed Inc (CRVO) Posted -118.68% Profit Margin Last Year—Can It Hold Up?
On Tuesday, CervoMed Inc (CRVO) stock saw a decline, ending the day at $2.16 which represents a decrease of $-8.09 or -78.93% from the prior close of $10.25. The stock opened at $2.53 and touched a ...